在缺乏 CD4⁺ 细胞条件下制备的 CD8⁺ CAR-T 细胞呈现低功能表型

Cell culture conditions during manufacturing can impact the clinical efficacy of chimeric antigen receptor (CAR) T cell products. Production methods have not been standardized because the optimal approach remains unknown. Separate CD4 + and CD8 + cultures offer a potential advantage but complicate manufacturing and may affect cell expansion and function. In a phase 1/2 clinical trial, we observed poor expansion of separate CD8 + cell cultures and hypothesized that coculture of CD4 + cells and CD8 + cells at a defined ratio at culture initiation would enhance CD8 + cell expansion and simplify manufacturing.

We generated CAR T cells either as separate CD4 + and CD8 + cells, or as combined cultures mixed in defined CD4:CD8 ratios at culture initiation. We assessed CAR T cell expansion, phenotype, function, gene expression, and in vivo activity of CAR T cells and compared these between separately expanded or mixed CAR T cell cultures.

We found that the coculture of CD8 + CAR T cells with CD4 + cells markedly improves CD8 + cell expansion, and further discovered that CD8 + cells cultured in isolation exhibit a hypofunctional phenotype and transcriptional signature compared with those in mixed cultures with CD4 + cells. Cocultured CAR T cells also confer superior antitumor activity in vivo compared with separately expanded cells. The positive impact of CD4 + cells on CD8 + cells was mediated through both cytokines and direct cell contact, including CD40L-CD40 and CD70-CD27 interactions.

Our data indicate that CD4 + cell help during cell culture maintains robust CD8 + CAR T cell function, with implications for clinical cell manufacturing.